Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-03-17Clinical Trial Update: A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab [Phase 1]
Phase 1 study of PF-05082566 as a single agent and with rituximab in various lymphomas; completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-03-10Clinical Trial Update: Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial of PNT2258 in relapsed or refractory non-Hodgkin's lymphoma completed; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-03-03Clinical Trial Update: A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
Clinical trial update on polatuzumab vedotin in combination with standard chemoimmunotherapy in B-cell non-Hodgkin's lymphoma (Phase 1/2) co…
-
CLINICAL_TRIALS trial_result · 2020-02-07Clinical Trial Update: LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma [Phase 1]
Phase 1 trial update on leukemia/lymphoma patients using LMP-specific T-cells for relapsed EBV-positive lymphoma; results posted for a compl…
-
CLINICAL_TRIALS trial_result · 2020-01-27Clinical Trial Update: Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL [Phase 1, Phase 2]
Clinical trial update on CD19 CAR-T therapy for acute lymphoblastic leukemia and non-Hodgkin lymphoma (Phase 1/Phase 2).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-01-21Clinical Trial Update: T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts [Phase 2]
A Phase 2 clinical trial evaluating T cell depletion in recipients of HLA haploidentical related donor stem cell grafts for various hematolo…
-
CLINICAL_TRIALS trial_result · 2020-01-21Clinical Trial Update: Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT [Phase 1]
Phase 1 trial exploring a calcineurin inhibitor-free graft-versus-host disease prevention regimen after related haploidentical peripheral bl…
-
CLINICAL_TRIALS trial_result · 2020-01-14Clinical Trial Update: Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma [Phase 2]
Phase 2 trial evaluating ROAD regimen (Oxaliplatin, Cytarabine, Dexamethasone) with Rituxan in relapsed non-Hodgkin lymphoma; trial complete…
-
CLINICAL_TRIALS trial_result · 2020-01-13Clinical Trial Update: Allo-hNHL (FluBuCy) [Phase 2]
Phase 2 clinical trial update for Allo-hNHL (FluBuCy) in Non-Hodgkin's Lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2020-01-03Clinical Trial Update: Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL [Phase 1, Phase 2]
Phase 1/2 trial evaluating VSLI plus rituximab in relapsed/refractory non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and mant…
-
CLINICAL_TRIALS trial_result · 2019-12-20Clinical Trial Update: Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating total-body irradiation and fludarabine phosphate followed by donor peripheral blood stem cell transpla…
-
CLINICAL_TRIALS trial_result · 2019-12-12Clinical Trial Update: Tenofovir to Prevent HBV Reactivation [Phase 3]
Phase 3 clinical trial update on using tenofovir to prevent hepatitis B reactivation in patients with hematologic malignancies.
-
CLINICAL_TRIALS trial_result · 2019-12-09Clinical Trial Update: Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant [Phase 2]
Phase 2 trial investigating sirolimus, cyclosporine, and mycophenolate mofetil to prevent graft-versus-host disease in patients with blood c…
-
CLINICAL_TRIALS trial_result · 2019-11-22Clinical Trial Update: Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies [Phase 2]
Phase 2 clinical trial assessing donor atorvastatin to prevent severe acute GVHD after nonmyeloablative peripheral blood stem cell transplan…
-
CLINICAL_TRIALS trial_result · 2019-11-08Clinical Trial Update: Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A combined Phase 1/2 trial evaluating lenalidomide after chemotherapy and stem cell transplant in various forms of recurrent or resistant no…
-
CLINICAL_TRIALS trial_result · 2019-10-22Clinical Trial Update: Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL [Phase 4]
Phase 4 trial investigating a PD-1 monoclonal antibody in combination with chemotherapy for relapsed/refractory non-Hodgkin's lymphoma.
-
CLINICAL_TRIALS trial_result · 2019-10-17Clinical Trial Update: Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 trial evaluating peripheral stem cell transplantation with combination chemotherapy in low-grade non-Hodgkin's lymphoma or chronic l…
-
CLINICAL_TRIALS trial_result · 2019-10-16Clinical Trial Update: Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial investigating lenalidomide and temsirolimus in relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma across Phase …
-
CLINICAL_TRIALS trial_result · 2019-09-12Clinical Trial Update: Combination of Rituximab and NK Immunotherapy for B Lymphoma [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating the combination of Rituximab with NK cell immunotherapy for recurrent B-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2019-09-06Clinical Trial Update: Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19 [Phase 1, Phase 2]
Clinical trial update for TriCAR-T_CD19 in refractory/relapsed non-Hodgkin lymphoma (Phase 1/Phase 2) with unknown status.
-
CLINICAL_TRIALS trial_result · 2019-08-28Clinical Trial Update: An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study [Phase 1, Phase 2]
An extension study of idelalisib (GS-1101) in subjects who benefited from prior idelalisib therapy; study terminated with results posted in …
-
CLINICAL_TRIALS trial_result · 2019-08-28Clinical Trial Update: Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL [Phase 2]
Phase 2 trial update for rituximab, yttrium Y-90 ibritumomab tiuxetan in relapsed follicular non-Hodgkin lymphoma (stages II-IV).
-
CLINICAL_TRIALS trial_result · 2019-08-14Clinical Trial Update: Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL [Phase 1, Phase 2]
Phase I/II trial investigating redox regulation in relapsed or refractory CD20+ non-Hodgkin's lymphoma has been terminated with results post…
-
CLINICAL_TRIALS trial_result · 2019-08-13Clinical Trial Update: Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) [Phase 3]
Phase 3 trial update for rituximab plus lenalidomide in relapsed/refractory indolent non-Hodgkin lymphoma (follicular lymphoma and marginal …
-
CLINICAL_TRIALS trial_result · 2019-08-06Clinical Trial Update: A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab [Phase 3]
A Phase 3 trial comparing maintenance subcutaneous rituximab to observation in relapsed/refractory indolent non-Hodgkin's lymphoma after rit…